Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Axitinib in Advanced Renal Cell Carcinoma
NCT03172754Phase 2Active, not recruiting
- Sponsor
- Fox Chase Cancer Center
- Start
- Jun 2017
- Primary completion
- Nov 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab and axitinib in renal cell carcinoma (RCC) (3 arms), sponsored by Fox Chase Cancer Center. Primary endpoints: Incidence of treatment-related adverse events at 15 months and Overall response rate at 12 months. Started Jun 2017; status: active, not recruiting.
02
Drugs
nivolumabaxitinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03172754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03172754.